Comparison of Myo-inositol Versus Metformin for Treating Obesity in Patients With Polycystic Ovarian Syndrome
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Reduction in body mass index
Study Overview
Brief Summary
There are considerable gaps in the comparative effectiveness and tolerability of myo-inositol and metformin for treating obesity in patients with polycystic ovarian syndrome (PCOS). The current study aimed to give insights comparing myo-inositol versus metformin for treating obesity in patients with PCOS.
Detailed Description
A review of the literature reveals inconsistent outcomes of myo-inositol vs metformin in the treatment of obesity and metabolic disorders in patients with PCOS, with comparable results and myo-inositol frequently demonstrating superior tolerability and reduced gastrointestinal side effects relative to metformin. When treating obesity in women with PCOS, practicing gynecologists would be able to select more appropriate medications by gathering data from local contexts. It will lessen psychological consequences associated with obesity, such as discrimination, stigma, low self-esteem, and poor quality of life.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Females aged 18-45 years
- •Diagnosed case of PCOS for more than 6 months of duration
Exclusion Criteria
- •Women with hyperprolactinemia or hypothyroidism (on history & medical record review)
- •Adrenal hyperplasia or Cushing's syndrome (on history & medical record review)
Arms & Interventions
Group-A
Women were given tablet myo-inositol 1 gm twice a day for 3 months.
Intervention: Myo-inositol (Drug)
Group-B
Women received metformin 250 mg three times daily for 3 months.
Intervention: Metformin (Drug)
Outcomes
Primary Outcomes
Reduction in body mass index
Time Frame: 3 months
A reduction in the body mass index with respect to baseline was taken as efficacy of the treatment.
Secondary Outcomes
No secondary outcomes reported
Investigators
Muhammad Aamir Latif
Research Consultant
RESnTEC, Institute of Research